A Review of the Toxicity of HIV Medications
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Watson, W. A., Litovitz, T. L., Rodgers, G. C., Klein-Schwartz, W., Reid, N., Youniss, J., Flanagan, A., & Wruk, K. M. (2005) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2005.05.001 · Cited by 1,148
Flexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Brown, T. T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1179 · Cited by 851
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 844
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022048 · Cited by 625
Kakuda, T. N. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)90004-3 · Cited by 612
Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
Côté, H. C. F., Brumme, Z. L., Craib, K. J. P., Alexander, C. S., Wynhoven, B., Ting, L., Wong, H., Harris, M., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012035 · Cited by 573
Neurological complications of HIV infection
McArthur, J. C., Brew, B. J., & Nath, A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70165-4 · Cited by 554
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
Cameron, D. W., Heath-Chiozzi, M., Danner, S., Cohen, C., Kravcik, S., Maurath, C., Sun, E., Henry, D., Rode, R., Potthoff, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)04161-5 · Cited by 536
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
Arnaudo, E., Shanske, S., DiMauro, S., Schon, E. A., Moraes, C. T., Schon, E. A., & Dalakas, M. (1991) · The Lancet · doi:10.1016/0140-6736(91)91294-5 · Cited by 505
Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective
Lewis, W., Day, B. J., & Copeland, W. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1201 · Cited by 498
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2009) · Clinical Toxicology · doi:10.3109/15563650903438566 · Cited by 485
Watson, W. A., Litovitz, T. L., Rodgers, G. C., Klein-schwartz, W., Youniss, J., Rose, S. R., Borys, D., & May, M. E. (2003) · The American Journal of Emergency Medicine · doi:10.1016/s0735-6757(03)00088-3 · Cited by 483
Birkus, G., Hitchcock, M. J. M., & Cihlar, T. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.716-723.2002 · Cited by 441
Association of tenofovir exposure with kidney disease risk in HIV infection
Scherzer, R., Estrella, M., Li, Y., Choi, A. I., Deeks, S. G., Grunfeld, C., & Shlipak, M. G. (2012) · AIDS · doi:10.1097/qad.0b013e328351f68f · Cited by 424
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Rumack, B. H., & Dart, R. C. (2012) · Clinical Toxicology · doi:10.3109/15563650.2012.746424 · Cited by 421
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Heard, S. E. (2008) · Clinical Toxicology · doi:10.1080/15563650802559632 · Cited by 415
Bartlett, K., & Eaton, S. (2004) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03947.x · Cited by 410
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Dart, R. C. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.635149 · Cited by 388
Bronstein, A. C., Spyker, D. A., Cantilena, L. R., Green, J. L., Rumack, B. H., & Giffin, S. L. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.543906 · Cited by 354
Fat Distribution in Men With HIV Infection
(2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000182230.47819.aa · Cited by 328
Crystalluria and Urinary Tract Abnormalities Associated with Indinavir
Kopp, J. B., Miller, K. D., Mican, J. A. M., Feuerstein, I. M., Vaughan, E., Baker, C., Pannell, L. K., & Falloon, J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-2-199707150-00004 · Cited by 312
A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection
Kinloch-de Loës, S., Hirschel, B. J., Hoen, B., Cooper, D. A., Tindall, B., Carr, A., Saurat, J.-H., Clumeck, N., Lazzarin, A., Mathiesen, L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508173330702 · Cited by 307
Bacellar, H., Muñoz, A., Miller, E. N., Cohen, B. A., Besley, D., Seines, O. A., Becker, J. T., & McArthur, J. C. (1994) · Neurology · doi:10.1212/wnl.44.10.1892 · Cited by 307
Mills, A., Nelson, M. R., Jayaweera, D. T., Ruxrungtham, K., Cassetti, I., Girard, P., Workman, C., Dierynck, I., Sekar, V. J., Abeele, C. V., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832d7350 · Cited by 268
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
John, M., Moore, C. B., James, I. R., Nolan, D., Upton, R. P., McKinnon, E. J., & Mallal, S. A. (2001) · AIDS · doi:10.1097/00002030-200104130-00007 · Cited by 264
Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis
Parienti, J., Bangsberg, D. R., Verdon, R., & Gardner, E. M. (2009) · Clinical Infectious Diseases · doi:10.1086/596482 · Cited by 244
Shafer, R. W., Smeaton, L. M., Robbins, G. K., De Gruttola, V., Snyder, S. W., D'Aquila, R. T., Johnson, V. A., Morse, G. D., Nokta, M. A., Martinez, A. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030265 · Cited by 228
Peripheral neuropathy and antiretroviral drugs
Dalakas, M. C. (2001) · Journal of the Peripheral Nervous System · doi:10.1046/j.1529-8027.2001.006001014.x · Cited by 224
Shikuma, C. M., Hu, N., Milne, C., Yost, F., Waslien, C., Shimizu, S., & Shiramizu, B. (2001) · AIDS · doi:10.1097/00002030-200109280-00009 · Cited by 213
Lonergan, J. T., Behling, C., Pfander, H., Hassanein, T. I., & Mathews, W. C. (2000) · Clinical Infectious Diseases · doi:10.1086/313912 · Cited by 208
Reviews Of Anti‐infective Agents: Maraviroc: The First of a New Class of Antiretroviral Agents
MacArthur, R. D., & Novak, R. M. (2008) · Clinical Infectious Diseases · doi:10.1086/589289 · Cited by 207
Moyle, G. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80064-8 · Cited by 193
Falcó, V., Rodríguez, D., Ribera, E., Martínez, E., Miró, J. M., Domingo, P., Diazaraque, R., José, R. A., González-García, J. J., Montero, F., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339041 · Cited by 181
HIV neuropathy natural history cohort study: Assessment measures and risk factors
Simpson, D. M., Kitch, D., Evans, S. R., McArthur, J. C., Asmuth, D. M., Cohen, B., Goodkin, K., Gerschenson, M., So, Y., Marra, C. M., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000218303.48113.5d · Cited by 178
HIV-Associated Peripheral Neuropathy: Epidemiology, Pathophysiology and Treatment
Wulff, E. A., Wang, A. K., & Simpson, D. M. (2000) · Drugs · doi:10.2165/00003495-200059060-00005 · Cited by 172
Raltegravir: The First HIV Type 1 Integrase Inhibitor
Hicks, C., & Gulick, R. M. (2009) · Clinical Infectious Diseases · doi:10.1086/597290 · Cited by 165
Browne, M. J., Mayer, K. H., Chafee, S. B. D., Dudley, M. N., Posner, M. R., Steinberg, S. M., Graham, K. K., Geletko, S. M., Zinner, S. H., Denman, S. L., et al. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.1.21 · Cited by 164
Mechanisms of Zidovudine-Induced Mitochondrial Toxicity and Myopathy
Scruggs, E. R., & Dirks‐Naylor, A. J. (2008) · Pharmacology · doi:10.1159/000134943 · Cited by 159
Fulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI)
Lai, K. K., Gang, D. L., Zawacki, J. K., & Cooley, T. P. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-4-283 · Cited by 157
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data
Cruciani, M., Zanichelli, V., Serpelloni, G., Bosco, O., Malena, M., Mazzi, R., Mengoli, C., Parisi, S. G., & Moyle, G. (2011) · AIDS · doi:10.1097/qad.0b013e328349c6ee · Cited by 154
Miró, Ò., López, S., Martínez, E., Pedrol, E., Milinkovic, A., Deig, E., Garrabou, G., Casademont, J., Gatell, J., & Cardellach, F. (2004) · Clinical Infectious Diseases · doi:10.1086/423176 · Cited by 150
Antiretroviral nucleoside and nucleotide analogues and mitochondria
Cossarizza, A., & Moyle, G. J. (2004) · AIDS · doi:10.1097/00002030-200401230-00002 · Cited by 144
The abacavir hypersensitivity reaction: A review
Clay, P. G. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80057-1 · Cited by 133
Coghlan, M. E., Sommadossi, J., Jhala, N. C., Many, W. J., Saag, M. S., & Johnson, V. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323783 · Cited by 132
McKeage, K., Perry, C. M., & Keam, S. J. (2009) · Drugs · doi:10.2165/00003495-200969040-00007 · Cited by 132
Kotler, D. P. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318186519c · Cited by 129
Moore, K. H. P., Barrett, J. E., Shaw, S., Pakes, G. E., Churchus, R., Kapoor, A., Lloyd, J., Barry, M. G., & Back, D. J. (1999) · AIDS · doi:10.1097/00002030-199911120-00006 · Cited by 128
Bardsley-Elliot (2000) · doi:10.2165/00003495-200059030-00014 · Cited by 127
Delavirdine: A Review of its Use in HIV Infection
Scott, L. J., & Perry, C. M. (2000) · Drugs · doi:10.2165/00003495-200060060-00013 · Cited by 115
Nagashima, K. A., Thompson, D. A. D., Rosenfield, S. I., Maddon, P. J., Dragic, T., & Olson, W. C. (2001) · The Journal of Infectious Diseases · doi:10.1086/319284 · Cited by 105
Chapman, T. M., McGavin, J. K., & Noble, S. (2003) · Drugs · doi:10.2165/00003495-200363150-00006 · Cited by 103
Plosker, G. L., & Noble, S. (1999) · Drugs · doi:10.2165/00003495-199958060-00011 · Cited by 101
Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS
Peters, B. S., Winer, J. B., LANDON, D. N., Stotter, A., & Pinching, A. J. (1993) · QJM · doi:10.1093/oxfordjournals.qjmed.a068738 · Cited by 99
Young, J., Schäfer, J., Fux, C. A., Furrer, H., Bernasconi, E., Vernazza, P., Calmy, A., Cavassini, M. L., Weber, R. K., Battegay, M., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32834f337c · Cited by 95
Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B Virus
Saravolatz, L. D., & Saag, M. S. (2005) · Clinical Infectious Diseases · doi:10.1086/498348 · Cited by 91
Lactic Acidosis International Study Group (2007) · AIDS · doi:10.1097/qad.0b013e3282f08cdc · Cited by 76
Murphy, R. L., da Silva, B. A., Hicks, C. B., Eron, J. J., Gulick, R. M., Thompson, M., McMillan, F., King, M. S., Hanna, G. J., & Brun, S. C. (2008) · HIV Clinical Trials · doi:10.1310/hct0901-1 · Cited by 70
Clinical Pharmacokinetics Of Nucleoside Antiretroviral Agents
Dudley, M. N. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.supplement_2.s99 · Cited by 69
Effects of the HIV Protease Inhibitor Ritonavir on GLUT4 Knock-out Mice
Vyas, A. K., Koster, J. C., Tzekov, A., & Hruz, P. W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.176321 · Cited by 66
Havlir, D. V., McLaughlin, M. M., & Richman, D. D. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.5.1379 · Cited by 62
Stanley, T. L., JOY, T. R., Hadigan, C. M., Liebau, J., Makimura, H., Chen, C. Y., Thomas, B. J., Weise, S. B., Robbins, G. K., & Grinspoon, S. K. (2009) · AIDS · doi:10.1097/qad.0b013e32832ba904 · Cited by 55
Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium
Nguyen, B., Isaacs, R., Teppler, H., Leavitt, R. Y., Sklar, P. A., Iwamoto, M., Wenning, L. A., Miller, M. D., Chen, J., Kemp, R. K., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05972.x · Cited by 55
Hruz, P. W. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283139134 · Cited by 49
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy
Calza, L., Manfredi, R., & Chiodo, F. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.03.009 · Cited by 48
l-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues
Claessens, Y.-É., Cariou, A., Chiche, J., Dauriat, G., & Dhainaut, J.-F. (2000) · AIDS · doi:10.1097/00002030-200003100-00029 · Cited by 47
Zidovudine Phosphorylation and Mitochondrial Toxicity in Vitro
Sales, S. D., Hoggard, P. G., Sunderland, D., Khoo, S., Hart, C. A., & Back, D. J. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9288 · Cited by 38
Crystalluria and Urinary Tract Abnormalities Associated With Indinavir
Kopp, J. B., Miller, K. D., Mican, J. A. M., Feuerstein, I. M., Vaughan, E. M., Baker, C., Pannell, L. K., & Falloon, J. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)62999-9 · Cited by 38
McDonald, C., Uy, J. P., Hu, W., Wirtz, V., Juethner, S., Butcher, D. L., McGrath, D., Farajallah, A., & Moyle, G. J. (2012) · AIDS Patient Care and STDs · doi:10.1089/apc.2011.0092 · Cited by 35
Deeks, E. D., & Keating, G. M. (2008) · Drugs · doi:10.2165/0003495-200868160-00007 · Cited by 35
Justice, A. C., Zingmond, D. S., Gordon, K. S., Fultz, S. L., Goulet, J. L., King, J. T., Bravata, D. M., Valdez, H., Kraft, M., Mattocks, K. M., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/592302 · Cited by 30
Role of integrase inhibitors in the treatment of HIV disease
Palmisano, L. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.1.67 · Cited by 26
The Nonnucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine in the Treatment of HIV
Michael, S. (2005) · HIV Clinical Trials · doi:10.1310/4kc0-56tm-vlbf-78bn · Cited by 15
Venhoff, N., Setzer, B., Lebrecht, D., & Walker, U. A. (2002) · AIDS · doi:10.1097/00002030-200203290-00021 · Cited by 14
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
“Nucleoside analogue reverse transcriptase inhibitors are liable to cause hepatotoxicity by interfering with mitochondrial function.(198) The incidence of severe hyperlactatemia with hepatic steatosis has been reported to be 0.”
BackgroundBerger, M. M., Shenkin, A., Schweinlin, A., Amrein, K., Augsburger, M., Biesalski, H.-K., Bischoff, S. C., Casaer, M. P., Gundogan, K., Lepp, H.-L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.02.015 · Cited by 615
Antiviral Natural Products and Herbal Medicines
Lin, L.-T., Hsu, W.-C., & Lin, C.-C. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124335 · Cited by 529
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Current status and prospects of HIV treatment
Cihlar, T., & Fordyce, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.004 · Cited by 337
Metadata
- Authors
- Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A.
- Venue
- Journal of Medical Toxicology
- Published
- 2013-08-21
- Volume
- 10
- Issue
- 1
- Pages
- 26-39
- ISSN
- 1556-9039 (ISSN-L)
- 1937-6995
- OpenAlex
- W2024643457
- Cited by
- 348
- References
- 81
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.